EWTX — Edgewise Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $2.50bn
- $1.94bn
- 52
- 24
- 93
- 58
Annual income statement for Edgewise Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 17.2 | 43.2 | 71.7 | 114 | 159 |
| Operating Profit | -17.2 | -43.2 | -71.7 | -114 | -159 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -17.1 | -42.8 | -67.6 | -100 | -134 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -17.1 | -42.8 | -67.6 | -100 | -134 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -17.1 | -42.8 | -67.6 | -100 | -134 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -17.1 | -42.8 | -67.6 | -100 | -134 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.36 | -1.14 | -1.26 | -1.57 | -1.45 |
| Dividends per Share |